Heart Failure Congress 2025
Heart Failure Congress 2025
Advertisement
Rob DillardHeart Failure | June 12, 2025
Patients experienced a median 57.6-month delay from first symptoms to ATTR-CM diagnosis, study finds.
Read More
CardioNerdsHeart Failure | June 12, 2025
MITT and safety data show acoramidis significantly lowers AFib-related events in transthyretin cardiac amyloidosis.
CardioNerdsHeart Failure Congress 2025 | June 5, 2025
ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
Rob DillardHeart Failure Congress 2025 | June 5, 2025
PVR severity is linked to higher short-term mortality in HFrEF, highlighting its role in risk stratification.
Rob DillardHeart Failure Congress 2025 | May 20, 2025
Checklist use for ATTR-CM "red flags" boosted diagnosis rates up to 10x in heart failure patients, study finds.
Rob DillardHeart Failure Congress 2025 | May 20, 2025
Heart failure affects over 640,000 kids and teens globally—urgent prevention and care policies are needed, study finds.
Rob DillardHeart Failure Congress 2025 | May 20, 2025
Waist-to-height ratio may better predict heart failure risk than BMI, new Heart Failure 2025 study finds.
Rob DillardHeart Failure Congress 2025 | May 20, 2025
Acoramidis rapidly boosts serum TTR levels in ATTR-CM patients, with effects sustained through 30 months, study shows.
Advertisement
Advertisement